nuBridges

NuBridge Therapeutics (also known as NuBridges) is a preclinical-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics using targeted protein degradation (TPD) and covalent chemistry. The company utilizes a proprietary covalent fragment-based drug discovery (CFBDD) platform to identify molecular glues and degraders for challenging targets in oncology. Its research primarily centers on E3 ligase modulation and the development of covalent inhibitors for oncogenic drivers like KRAS. NuBridge Therapeutics aims to address 'undruggable' proteins to provide new treatment options for patients with solid tumors and hematological malignancies. The company is backed by prominent investors including Sequoia China and Hillhouse's GL Ventures.